港股频道更多独家策划、专家专栏，免费查阅>>责任编辑：山上 10月27日，恒瑞医药(1276.HK)今日早盘一度涨5.21%至80.8港元。恒瑞医药公告，江苏恒瑞医药股份有限公司子公司山东盛 迪医药有限公司近日收到国家药品监督管理局的通知，批准公司恒格列净瑞格列汀二甲双胍缓释片(Ⅰ)、(Ⅱ)(HR20031片) 上市，该产品是中国首个自主研发的口服降糖三药联合固定复方制剂。用于经盐酸二甲双胍治疗血糖控制不佳的成人2型糖 尿病患者改善血糖控制。 银河证券研报认为，医药板块估值经历较长时间调整，近期已呈现显著结构性修复趋势，但公募基金重仓持仓水平仍低于 历史均值，2025年在支持引导商保发展的政策背景下，支付端有望边际改善，创新药械有望获益。展望后市，该行持续看 好医药创新，下半年创新药BD仍将持续，医药投融资有望复苏，CXO及上游景气度持续向好。 ...

恒瑞医药(1276.HK)今日早盘一度涨5.21%至80.8港元。恒瑞医药公告，江苏恒瑞医药股份有限公司子公司山东盛迪医药有限公司近日收到国家药品监督管理 局的通知，批准公司恒格列净瑞格列汀二甲双胍缓释片(Ⅰ)、(Ⅱ)(HR20031片)上市，该产品是中国首个自主研发的口服降糖三药联合固定复方制剂。用于经 盐酸二甲双胍治疗血糖控制不佳的成人2型糖尿病患者改善血糖控制。 银河证券研报认为，医药板块估值经历较长时间调整，近期已呈现显著结构性修复趋势，但公募基金重仓持仓水平仍低于历史均值，2025年在支持引导商保 发展的政策背景下，支付端有望边际改善，创新药械有望获益。展望后市，该行持续看好医药创新，下半年创新药BD仍将持续，医药投融资有望复苏， CXO及上游景气度持续向好。(格隆汇) ...

Major Events - Cambridge Technology (06166) sets the offer price for H-shares at HKD 68.88 per share [1] - Sany Heavy Industry (06031) sets the offer price for H-shares at HKD 21.30 per share [1] - Hengrui Medicine (01276) receives approval for the launch of HR20031 tablets [1] - Shanghai Pharmaceuticals (02607) subsidiary becomes the holder of the marketing authorization for amisulpride orally disintegrating tablets [1] - Fosun Pharma (02196) receives registration approval for Delarobert tablets and Delarobert granules [1] - WuXi AppTec (02359) plans to sell 100% equity of Kande Hongyi and Jinshi Medicine [1] - Hengfu Holdings (00643) receives a buyout offer at a discount of approximately 79.20% and will resume trading on October 27 [1] Operating Performance - Chifeng Jilong Gold Mining (06693) reports Q3 net profit of CNY 951 million, a year-on-year increase of 140.98% [1] - WuXi AppTec (02359) reports a net profit of CNY 12.076 billion for the first three quarters, up 84.84% year-on-year [1] - Huaxin Cement (06655) reports a net profit of CNY 2.004 billion for the first three quarters, a year-on-year increase of 76.01% [1] - Luoyang Molybdenum (03993) reports a net profit of approximately CNY 14.28 billion for the first three quarters, up 72.61% year-on-year [1] - Goldwind Technology (02208) reports a net profit of approximately CNY 2.584 billion for the first three quarters, a year-on-year increase of 44.21% [1] - CITIC Securities (06030) reports a net profit of approximately CNY 23.159 billion for the first three quarters, up 37.86% year-on-year [1] - Kingdee International (00268) reports annual recurring revenue of approximately CNY 3.86 billion from subscription services for the first three quarters, a year-on-year increase of about 18% [1] - China Nonferrous Mining (01258) estimates a profit of approximately USD 356 million for the first three quarters, a year-on-year increase of about 13% [1] - Chongqing Bank (01963) reports a net profit of CNY 4.879 billion for the first three quarters, a year-on-year increase of 10.19% [1] - China Resources Cement (01313) reports a profit attributable to shareholders of CNY 331 million for the first three quarters, a year-on-year increase of 7.3% [1] - China Shenhua Energy (01088) reports a net profit of CNY 41.366 billion for the first three quarters, a year-on-year decrease of 13.8% [1] - Haohai Biological Technology (06826) reports a net profit of approximately CNY 305 million for the first three quarters, a year-on-year decrease of 10.63% [1] - Great Wall Motors (02333) reports a net profit of CNY 2.298 billion for the third quarter, a year-on-year decrease of 31.23% [1] - China Heart and Heart Fertilizer (01866) reports a net profit of approximately CNY 800 million for the first three quarters, a year-on-year decrease of 47.86% [1] - China National Building Material (03323) reports a net profit of CNY 2.96 billion for the first three quarters [1] - GAC Group (02238) reports a net loss of approximately CNY 4.312 billion for the first three quarters, a shift from profit to loss year-on-year [1] - China Overseas Development (00688) reports revenue of CNY 103 billion and operating profit of CNY 13.15 billion for the first three quarters [1] - Haifeng International (01308) reports revenue of approximately USD 2.459 billion for the first three quarters, a year-on-year increase of approximately 16.6% [1] - China Energy Engineering (03996) reports a cumulative new contract amount of CNY 992.775 billion for the first three quarters, a year-on-year increase of 0.4% [1] E-commerce Performance - Li Ning (02331) reports high double-digit growth in its e-commerce virtual store business for the third quarter [2]

Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the launch of HR20031 tablets, which are indicated for improving blood sugar control in adults with type 2 diabetes who have inadequate control with metformin [1] Company Summary - Heng Rui Medicine (600276) announced the approval of its HR20031 tablets, which combine empagliflozin, linagliptin, and metformin [1] - The approved indication for HR20031 is to be used in conjunction with diet control and exercise for adult patients with type 2 diabetes [1] Industry Summary - The approval of HR20031 tablets reflects ongoing advancements in diabetes treatment options within the pharmaceutical industry [1] - The product aims to address the needs of patients with type 2 diabetes who struggle with blood sugar control despite existing treatments [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for its innovative oral diabetes medication, marking a significant advancement in the treatment of type 2 diabetes in China [1] Group 1: Product Information - The approved product is named Henggeli Jing Ruige Liting Metformin Sustained-Release Tablets (I) and (II) [1] - It is the first self-developed fixed-dose combination of three oral hypoglycemic agents in China [1] - The product is classified as a chemical drug of category 2.3, with specifications of 5/50/750 mg and 10/100/1000 mg [1] Group 2: Indications and Usage - The approved indication for the product is to improve blood sugar control in adult patients with type 2 diabetes who have inadequate blood sugar control with metformin hydrochloride, in conjunction with diet and exercise [1] - It is categorized as a prescription drug [1]

目前，糖尿病已经成为继肿瘤、心脑血管病之后第三位严重危害人类健康的慢性疾病。国际糖尿病联盟 (IDF)第11版数据显示，中国成人(20-79岁)糖尿病患病率达13.79%，患者数量达1.48亿，已经成为糖尿 病第一大国，其中2型糖尿病(T2DM)患者临床用药依从性不佳，血糖控制率仅有50.1%。HR20031片是 脯氨酸恒格列净、磷酸瑞格列汀和盐酸二甲双胍的固定复方制剂，有望通过三种不同作用机制达到降血 糖作用，拟每日一次口服用于治疗经二甲双胍治疗血糖控制不佳的成人2型糖尿病患者，可通过减少服 药数量简化降糖方案，提高患者的治疗依从性。经查询，国外已上市的同类三药联合固定复方制剂有勃 林格殷格翰-礼来糖尿病联盟的TRIJARDY XR(恩格列净/利格列汀/盐酸二甲双胍缓释片)，国内尚无同 类产品获批上市。截至目前，HR20031片相关项目累计研发投入约18,924万元。 恒瑞医药（600276）(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称"公司")子公司山东 盛迪医药有限公司收到国家药品监督管理局(以下简称"国家药监局")的通知，批准公司恒格列净瑞格列 汀二甲双胍缓释片(Ⅰ)、(Ⅱ)(HR ...

目前，糖尿病已经成为继肿瘤、心脑血管病之后第三位严重危害人类健康的慢性疾病。国际糖尿病联盟 (IDF)第 11 版数据显示，中国成人(20-79 岁)糖尿病患病率达 13.79%，患者数量达 1.48 亿，已经成为糖 尿病第一大国，其中 2 型糖尿病(T2DM)患者临床用药依从性不佳，血糖控制率仅有 50.1%。HR20031 片是脯氨酸恒格列净、磷酸瑞格列汀和盐酸二甲双胍的固定复方制剂，有望通过三种不同作用机制达到 降血糖作用，拟每日一次口服用于治疗经二甲双胍治疗血糖控制不佳的成人 2 型糖尿病患者，可通过减 少服药数量简化降糖方案，提高患者的治疗依从性。经查询，国外已上市的同类三药联合固定复方制剂 有勃林格殷格翰-礼来糖尿病联盟的 TRIJARDY XR(恩格列净/利格列汀/盐酸二甲双胍缓释片)，国内尚 无同类产品获批上市。截至目前，HR20031 片相关项目累计研发投入约 18,924 万元。 智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称"公司")子公 司山东盛迪医药有限公司收到国家药品监督管理局(以下简称"国家药监局")的通知，批准公司恒格列净 瑞格列汀二 ...

Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the launch of its oral hypoglycemic drug, HR20031, which is the first self-developed fixed-dose combination of three oral hypoglycemic agents in China [1] Company Summary - The approved product, HR20031, is a combination of empagliflozin, linagliptin, and metformin extended-release tablets [1] - It is indicated for adult patients with type 2 diabetes who have inadequate blood sugar control with metformin hydrochloride, in conjunction with diet and exercise [1] - This marks a significant milestone as there are currently no similar products approved for sale in the domestic market [1]